In 47 TRAPS patients from the US, the European Union, and the eastern Mediterranean, treatment with anakinra versus anti-TNF agents as the first biologic therapy led to significantly higher clinical and biochemical responses [27]. The gene discussed is TNF; the disease is TNF receptor 1-associated periodic fever syndrome.